Apexian Pharmaceuticals is an emerging clinical stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided unique insight into this important biological target. Dr. Kelley’s research, and the research of other scientists worldwide, has shown that inhibitors of APE1/Ref-1 redox signaling affect numerous transcription factors involved in cancer cell signaling and survival.
Apexian has leveraged this deep scientific expertise to discover molecules that target and inhibit the APE1/Ref-1 redox signaling and DNA repair protein pathway with high specificity. Our lead molecule – APX3330 – is representative of this novel class of compounds, and has shown dramatic single-agent efficacy in pre-clinical cancer models, including models of human pancreatic cancer. Additionally, pre-clinical studies indicate that APX3330 is synergistic with a number of chemotherapeutic agents while providing evidence of a neuro-protective effect.
The preliminary testing of human safety and non-cancer efficacy of APX3330 was established by Eisai Pharmaceuticals in a previously conducted development program targeting chronic liver diseases, where the compound was safely administered in over 10 clinical trials to more than 400 patients, across a variety of doses. Apexian has utilized this historical data to develop an accelerated plan for testing APX3330 in patients with advanced APE1/Ref-1 expressing cancers.